October 30, 2020
Denka Company Limited
Expansion of Specimen Types for Influenza Rapid Antigen Test
～For acceleration of simultaneous detection of both influenza and SARS-CoV-2 by expanding and clarifying
specimen types for the test～

On October 30th, Denka Company Limited (headquarters: Chuo-ku, Tokyo; president: Manabu Yamamoto; hereinafter,“Denka”) has received approval from the Ministry of Health, Labour and Welfare to partially change the market
authorization for QuickNaviTM-Flu2, an influenza rapid antigen test*. The approval enables the use of a nasal swab
specimen for QuickNaviTM-Flu2 and as a result, now both influenza and SARS-CoV-2 can be tested with a single
specimen, which is recommended by the Japanese Association for Infectious Diseases. This expansion of specimen type is
expected to accelerate the current diagnostic systems in clinics and hospitals.
As with QuickNaviTM-COVID19 Ag, a nasal swab specimen collected by a patient has been allowed to be used with
QuickNaviTM-Flu2 under supervision of a healthcare professional. This will reduce of the risk of transmission to healthcare
professionals and the burden on patients. Approval of this partial change also applies to products marketed by ourdistributor, Otsuka Pharmaceutical Co., Ltd. (headquarters: Chiyoda-ku, Tokyo; president: Makoto Inoue).

* Description change:
Previous: nasal swab specimen → New: nasopharyngeal swab specimen and nasal swab specimen

Specimen type

QuickNavi™-Flu2

QucikNavi™ -COVID19 Ag

Nasopharyngeal swab specimen○○

Nasal swab specimen○○Denka considers the fight against infectious diseases to be its social responsibility and, with the cooperation and supportof relevant authorities, public agencies and research institutions in Japan and overseas, is conducting research anddevelopment from various perspectives to meet the needs of healthcare professionals and contribute people’s quality of lifeby help improve prevention and diagnostic systems. Denka will promptly make an announcement if this development isexpected to have a material impact on Denka’s consolidated financial results for FY2020.
* COVID-19 Pathogen Testing Guideline (First Edition) and notes on collecting a sample from nasal cavity, COVID-19
Control Task Force, Ministry of Health, Labour and Welfare (October 2, 2020) *Japanese
https://www.mhlw.go.jp/content/000678570.pdf
Reference: Related past release (Denka’s website):・October 2, 2020, Expansion of Intended Use and Specimen Types for Denka's COVID 19 Ag Rapid Test kit~To diminish healthcare and patient burden in SARS-CoV-2 and Influenza antigen testing~https://www.denka.co.jp/storage/news/pdf/768/20201002_denka_quicknavi.pdf
About Denka
Denka is a chemical manufacturer headquartered in Chuo-ku, Tokyo. The company specializes in developing businessactivities on a global scale across a wide range of fields, from inorganic and organic chemicals, to electronic materials andpharmaceuticals. Founded in 1915, Denka has steadily continued to develop and manufacture products that contribute to
the development of society by fully utilizing its unique concepts and technological capabilities. Upholding its corporate
slogan, “Possibility of chemistry,” the company and its president, Manabu Yamamoto, are committed to contributing to
the sound development of society while sincerely tackling the challenges that society is now confronting.

[For Inquiries about This Press Release from Media]
Corporate Communications Dept.

Tel : +81-3-5290-5511[For Inquiries from Medical Personnel]
Life Innovation Dept. Vaccines and Diagnostics Business Headquarters Dept. Tel : +81-3-6214-3235